6.73
0.30%
0.02
시간 외 거래:
6.73
전일 마감가:
$6.71
열려 있는:
$6.69
하루 거래량:
45,552
Relative Volume:
0.58
시가총액:
$386.92M
수익:
$154.57M
순이익/손실:
$15.07M
주가수익비율:
24.93
EPS:
0.27
순현금흐름:
$10.92M
1주 성능:
-6.40%
1개월 성능:
+10.51%
6개월 성능:
+19.12%
1년 성능:
+17.45%
Kamada Ltd Stock (KMDA) Company Profile
KMDA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
6.73 | 386.92M | 154.57M | 15.07M | 10.92M | 0.27 |
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-07-03 | 개시 | Stifel | Buy |
2018-02-02 | 개시 | Chardan Capital Markets | Buy |
Kamada Ltd 주식(KMDA)의 최신 뉴스
Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 33.3% in January - MarketBeat
High Growth Tech Stocks To Watch In January 2025 - Simply Wall St
Kamada to supply immune globulin products in Latin America - Pharmaceutical Business Review
Kamada secures $25 million Latin America contract - MSN
Kamada Secures $25 Million Contract for Immune Globulin Products in Latin America - TipRanks
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America - The Manila Times
Kamada Secures Major $25M Contract for Life-Saving Immunoglobulin Drugs in Latin America - StockTitan
Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 33.3% in December - MarketBeat
Kamada’s (KMDA) Buy Rating Reiterated at HC Wainwright - Defense World
Market Participants Recognise Kamada Ltd.'s (TLV:KMDA) Earnings Pushing Shares 25% Higher - Simply Wall St
Kamada's (KMDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations - Yahoo Finance
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025 - GlobeNewswire
Kamada Projects Strong 2025 Growth: 13% Revenue Jump to $182M, EBITDA to Rise 19% - StockTitan
KMDA stock touches 52-week high at $6.53 amid market optimism By Investing.com - Investing.com South Africa
Kamada (NASDAQ:KMDA) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Comparing Endonovo Therapeutics (OTCMKTS:ENDVD) & Kamada (NASDAQ:KMDA) - Defense World
KMDA stock touches 52-week high at $6.53 amid market optimism - Investing.com Australia
Financial Survey: Kamada (NASDAQ:KMDA) versus Endonovo Therapeutics (OTCMKTS:ENDVD) - Defense World
Exploring High Growth Tech Stocks This January 2025 - Yahoo Finance
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - The Manila Times
Exploring Undiscovered Gems with Potential This December 2024 - Simply Wall St
So who replaces Eberechi Eze against Arsenal? Crystal Palace boss asked if summer signing will step in - South London News
Music Industry Moves: Avex USA Names Ryusuke Kamada CFO - Yahoo Entertainment
Kamada Ltd. Approves Board Re-Elections and Auditor Appointment - TipRanks
Gauzy Appoints Lilach Payorski to Board - Glass Magazine
Gauzy Adds to Board of Directors - CleanLink
Here's Why Shareholders May Want To Be Cautious With Increasing Kamada Ltd.'s (TLV:KMDA) CEO Pay Packet - Simply Wall St
Short Interest in Kamada Ltd. (NASDAQ:KMDA) Expands By 8.9% - Defense World
Gauzy Appoints Seasoned Public Company Executive and Director Lilach Payorski to Board of Directors - The Manila Times
Gauzy Strengthens Board with Ex-Stratasys CFO Lilach Payorski as Audit Chair | GAUZ Stock News - StockTitan
Maxkamada Banaadir oo soo saartay Waaran lagu soo xirayo Madaxweynaha Jubaland - Horseed Media
Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business - Simply Wall St
Alpha 1 Antitrypsin Deficiency Treatment Market Analysis By Top - openPR
HC Wainwright Issues Pessimistic Outlook for Kamada Earnings - MarketBeat
What is HC Wainwright’s Forecast for Kamada FY2024 Earnings? - Defense World
Alpha-1 Antitrypsin Deficiency Therapy Market 2024-2031 - openPR
HC Wainwright Forecasts Kamada's Q4 Earnings (NASDAQ:KMDA) - MarketBeat
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook - Investing.com India
Phoenix Financial Ltd. Increases Stake in Kamada Ltd. - GuruFocus.com
Kamada Ltd. (NASDAQ:KMDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ... - Yahoo Finance
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Reven - GuruFocus.com
Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market to Grow - openPR
Alpha-1 Antitrypsin Deficiency Market Expected to Experience Major Growth by 2034, According to DelveInsight | Kamada Pharma, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex - Barchart
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook By Investing.com - Investing.com Australia
Kamada Ltd (KMDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):